HR 4866
116th Congress
House
Health
Advanced technology and technological innovations
Congressional oversight
Drug safety, medical device, and laboratory regulation
Government information and archives
Health programs administration and funding
Health technology, devices, supplies
Higher education
Manufacturing
Prescription drugs
Product development and innovation
Research administration and funding
Research and development
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
Introduced: October 28, 2019
Introduced by:
Pallone, Frank
Democratic
· New Jersey
See on congress.gov
Everywhere this bill has been
16 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 22, 2020
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 21, 2020
Mrs. Dingell moved to suspend the rules and pass the bill, as amended.
Sep 21, 2020
Considered under suspension of the rules. (consideration: CR H4616-4618)
Sep 21, 2020
DEBATE - The House proceeded with forty minutes of debate on H.R. 4866.
Sep 21, 2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Sep 21, 2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4616-4617)
Sep 21, 2020
Motion to reconsider laid on the table Agreed to without objection.
Sep 17, 2020
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-513.
Sep 17, 2020
Placed on the Union Calendar, Calendar No. 413.
Jul 15, 2020
Committee Consideration and Mark-up Session Held.
Jul 15, 2020
Ordered to be Reported (Amended) by Voice Vote.
Mar 11, 2020
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Mar 11, 2020
Subcommittee Consideration and Mark-up Session Held.
Oct 29, 2019
Referred to the Subcommittee on Health.
Oct 28, 2019
Referred to the House Committee on Energy and Commerce.
Oct 28, 2019
Introduced in House
Plain-English summary
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019
This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)
What's happening now
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
3
Cosponsors
1